1. A phase 1/PK study of Sunitinib with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors: AIDS malignancy consortium study 061
- Author
-
Ryan J. Sullivan, Ronald T. Mitsuyasu, Mary Cianfrocca, Richard F. Little, Lee Ratner, S. P. Ivy, Page C. Moore, John F. Gerecitano, Bruce J. Dezube, John F. Deeken, Michelle A. Rudek, David H. Henry, David M. Aboulafia, Kimberly Mosby, and Melinda Tibbals
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Epidemiology ,medicine.drug_class ,medicine.medical_treatment ,lcsh:RC254-282 ,Tyrosine-kinase inhibitor ,lcsh:Infectious and parasitic diseases ,Pharmacokinetics ,Internal medicine ,Medicine ,lcsh:RC109-216 ,Dosing ,Chemotherapy ,AIDS Malignancy Consortium ,business.industry ,Sunitinib ,Cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Infectious Diseases ,Hiv patients ,Oral Presentation ,business ,medicine.drug - Abstract
Background In developed counties the rates of non-AIDS defining cancers (NADCs) now exceed those of AIDS-defining cancers in HIV-positive patients. Drug-drug interactions between HAART and chemotherapy may complicate the treatment of patients with NADCs. In order to determine the proper dosing of new targeted chemotherapies in patients with NADCs who are also on HAART, the AMC is performing a series of phase I/pharmacokinetic (PK) studies to determine the proper dosing of these agents in HIV+ cancer patients. We present the results of the first such study which investigated sunitinib, an oral multiple tyrosine kinase inhibitor.
- Published
- 2012